The biotechnology sector continues to witness substantial momentum in the spatial omics and artificial intelligence space, with OmicInsight Corporation announcing a significant strategic investment round led by LOTTE Holdings through its Healthcare & Biopharmaceutical Corporate Venture Capital arm. The Santa Clara-based company, which specializes in AI-driven high-sensitivity spatial omics analysis, secured funding that includes participation from a healthcare-focused private investment firm and returning investor Adelphi Ventures. This capital injection is designed to accelerate OmicInsight’s business roadmap, including the expansion of AI-driven diagnostics and premium subcellular-level, multi-omics analysis at scale.
Build the future you deserve. Get started with our top-tier Online courses: ACCA, HESI A2, ATI TEAS 7, HESI EXIT, NCLEX-RN, NCLEX-PN, and Financial Literacy. Let Serrari Ed guide your path to success. Enroll today.
Strategic Investment Positions OmicInsight for Global Expansion
The investment marks a pivotal moment for OmicInsight as it seeks to bridge the gap between complex biological data and actionable therapeutic insights for the pharmaceutical industry. Dr. Joon Paek, Managing Partner of the LOTTE Holdings Healthcare & Biopharmaceutical CVC, expressed confidence in the company’s technological capabilities, noting that OmicInsight’s spatial omics imaging technology and its strategic pivot to translational research and AI platform development will drive significant impact in the pharmaceutical industry.
The funding arrives at a critical juncture for the spatial biology market, which is experiencing rapid growth driven by technological advancements and increasing applications in precision medicine. According to market research published by Business Wire, the spatial biology market is positioning itself as a cornerstone of modern biomedical research and clinical translation, offering powerful, non-destructive tools to map the complexity of tissues with single-cell resolution.
LOTTE Holdings Expands Healthcare Investment Portfolio
LOTTE Holdings established its Healthcare and Biopharmaceutical CVC in July 2024 with a mission to support and invest in startup companies developing innovative healthcare technologies. The Tokyo-based conglomerate, led by CEO Genichi Tamatsuka, operates a diverse global portfolio spanning food, retail, biopharmaceuticals, and healthcare sectors across approximately 30 countries and regions worldwide.
The investment in OmicInsight represents LOTTE Holdings’ continued commitment to advancing healthcare innovation and addressing global health challenges through strategic venture capital deployment. The conglomerate previously entered the healthcare and biopharmaceutical sector in 2022 by establishing LOTTE BIOLOGICS, a Contract Development and Manufacturing Organization (CDMO) that has been expanding its competitiveness in the biopharmaceutical manufacturing market.
LOTTE Holdings has been actively building its healthcare investment portfolio through strategic deployments. The CVC arm has previously invested in Physiologas Technologies, a Japanese medical device company developing next-generation hemodialysis systems, marking its first investment in the medical device sector. The venture capital arm also invested in Cartography Biosciences, a preclinical-stage company developing AI and machine learning-powered drug discovery platforms for cancer treatment.
OmicInsight’s Technology Roots and Evolution
OmicInsight Corporation was established based on the core intellectual property of Rebus Biosystems, a venture-backed Silicon Valley life science technology company that pioneered revolutionary tools for spatial omics research. The company’s proprietary technology enables high-resolution imaging of DNA and RNA distributions, with its AI-powered microscope platform already in use by major pharmaceutical companies including Genentech.
The technology builds upon Rebus Biosystems’ patented Synthetic Aperture Optics (SAO) system, which provides the resolution and sensitivity of a 100X oil lens while maintaining the breadth and depth of a 20X air lens. This innovation enables data capture at speeds 100 times faster than other imaging-based spatial omics methods that rely on conventional lenses and z-stacking techniques. The platform delivers quantitative single molecule, single-cell data with subcellular resolution, combining advanced imaging, on-system chemistry, and intuitive software to provide an end-to-end solution requiring minimal hands-on time.
The foundational technology has attracted significant investment over the years, drawing approximately $54 million in investments from industry leaders such as California-based Illumina Ventures. This investor confidence reflects the broader market recognition of spatial biology’s transformative potential in advancing drug discovery and precision medicine applications.
Dual-CEO Leadership Driving Commercial Expansion
OmicInsight operates under a dual-leadership structure, with Dr. Josh Ryu and Jae Won Kim serving as Co-CEOs. In October 2025, the company announced the appointment of Jae Won Kim as Co-Chief Executive Officer to drive global strategy and partnerships alongside Dr. Ryu, who provides visionary technical leadership.
Jae Won Kim brings over 15 years of distinguished experience in the healthcare industry as a C-suite executive, venture partner, and investment banker, having advised companies on mergers and acquisitions and financing for a total transaction value exceeding $15 billion. Most recently, as VantAI’s COO and CFO, she closed major transactions including the expansion of a collaboration with Blueprint Medicines for a potential value exceeding $1.67 billion.
Ted Jeong, Chairman of the Board at OmicInsight Corporation, emphasized the strategic importance of the dual-CEO model, noting that it ensures both rapid technological advancement and disciplined, strategic commercial execution, positioning the company for exponential global success.
The Growing Spatial Omics Market Opportunity
The spatial omics market represents one of the most dynamic segments in biotechnology, with substantial growth projected over the coming years. Market analysis indicates the global spatial omics market reached $497.60 million in 2025 and is projected to reach $829.81 million by 2030, representing a compound annual growth rate of 10.77% during the forecast period.
The robust momentum in the sector stems from fast-maturing spatial transcriptomics, proteomics, and genomics technologies, widening precision medicine use cases, and sustained public funding. North America retains dominance thanks to research infrastructure and regulatory clarity, while Asia-Pacific delivers the quickest expansion, reflecting strong biopharma investment in the region.
Strategic acquisitions have characterized the competitive landscape, with major deals such as Bruker’s purchase of NanoString and Quanterix’s bid for Akoya underscoring an arms race for full-stack spatial biology capabilities. The consolidation trend reflects the industry’s recognition that comprehensive, end-to-end solutions will be essential for capturing market share in the evolving precision medicine landscape.
Market projections from SNS Insider suggest the global spatial omics market could reach $1.31 billion by 2032, growing at a CAGR of 12.55% over the forecast period. The United States led the market in 2023, accounting for over 81% of the market share, with demand propelled by increasing utilization of precision medicine and the necessary detailed molecular tissue-level knowledge.
One decision can change your entire career. Take that step with our Online courses in ACCA, HESI A2, ATI TEAS 7, HESI EXIT, NCLEX-RN, NCLEX-PN, and Financial Literacy. Join Serrari Ed and start building your brighter future today.
AI Integration Transforming Drug Discovery
The integration of artificial intelligence with spatial omics technologies represents a fundamental shift in pharmaceutical research and development. AI enables integration of multi-omics data, including genomics, transcriptomics, proteomics, and metabolomics, to uncover hidden patterns and identify promising therapeutic targets that traditional methods might miss.
The global AI market in precision medicine is anticipated to reach approximately $49.49 billion by 2034, growing at a CAGR of 35.80% from 2025 to 2034. This explosive growth reflects the transformative potential of AI algorithms to analyze complex medical data, identify diseases at earlier stages, and improve patient outcomes through more targeted treatment approaches.
Industry experts predict that 2025 will mark a turning point for AI in precision oncology, with the first AI-discovered or AI-designed therapeutic oncology candidates potentially entering first-in-human trials. This development signals a paradigm shift in how therapies are developed, moving from empirical to computationally guided therapeutic development.
The pharmaceutical industry has embraced AI integration, with major players like AstraZeneca committing more than $1 billion in AI partnerships over recent years. Predictive AI in drug discovery represents what industry experts call the holy grail, enabling identification of potentially useful molecules in 30 days or less compared to the months or years traditionally required in wet lab settings.
Biopharma Applications and Commercial Strategy
OmicInsight aims to expand partnerships in the biopharma industry to provide pharmaceutical companies with its proprietary technology for end-to-end drug discovery. By leveraging the extensive global networks of its new and existing partners, the company seeks to expand its customer base and bring its high-resolution multi-omic data solutions to the forefront of global drug discovery efforts.
The pharmaceutical and biotech industry represents the largest and fastest-growing user segment for spatial omics applications, particularly in clinical trials, biomarker discovery, and drug development pipeline applications. This shift suggests an emerging market in which research results are moving increasingly into actual therapy development.
Spatial biology-based image analysis offers insights into mechanisms of action and therapeutic efficacy for drug development, with applications extending to biomarker discovery and clinical diagnostics that enhance precision medicine capabilities. The technology enables researchers to study how cells, molecules, and biological processes are organized and interact within their native tissue environments, providing unprecedented insights into disease mechanisms, cellular interactions, and tissue architecture.
The 3rd Spatial Biology for Drug Development Summit highlights the growing industry focus on harnessing spatial biology technologies to identify drug targets, enhance biomarker discovery, and improve translational research. Across intensive conference agendas, biopharma experts explore practical solutions to issues spanning data infrastructure, multi-omics integration, standardization, scalability, and translation into clinical applications.
Investor Landscape and Funding Dynamics
Adelphi Ventures, the existing investor participating in the current round, is a cross-border venture capital firm founded in 2024 that focuses on biotechnology, healthcare, and food technology investments. Based in Bethesda, Maryland, the firm specializes in fostering cross-border partnerships in biotech and has played a key role in supporting OmicInsight’s development from its earliest stages.
The broader biotechnology investment landscape shows continued momentum despite market volatility in recent years. Global biotech investments are projected to surge from $483 billion in 2024 to $546 billion by 2025, representing an impressive 13% compound annual growth rate. This growth is driven by a convergence of scientific breakthroughs, increased public and private funding, and a renewed focus on pandemic preparedness and precision medicine.
Investors are focusing on programs with proven science, robust biomarker data, and well-defined regulatory and commercialization pathways. While substantial funding remains available, investors have become more selective, channeling resources into the most promising therapeutic areas, especially advanced therapies with validated targets and strong biomarker evidence.
Precision Medicine Market Growth
The global precision medicine market is experiencing substantial expansion, with market size calculated at $101.86 billion in 2024 and projected to reach $463.11 billion by 2034. The market is expanding at a CAGR of 16.35% between 2025 and 2034, driven by technological advancements such as artificial intelligence and next-generation sequencing that enable more accurate and personalized treatments.
Collaborations between pharmaceutical companies and technology firms are enhancing data analytics capabilities, facilitating the development of targeted therapies. Additionally, supportive government initiatives and increased funding for research are accelerating the adoption of precision medicine, particularly in oncology and rare disease applications.
The precision medicine market has attracted over $12.4 billion in capital from leading investors, with notable contributors including Orbimed, Boehringer Ingelheim, Eli Lilly, and Nice Investment Partners. This investment landscape reflects confidence in the sector’s future growth and its potential to transform healthcare delivery through personalized approaches.
Multi-Omics Integration Driving Innovation
The future of precision medicine increasingly depends on multi-omics integration, which combines multiple levels of biology, including genomics, transcriptomics, proteomics, and metabolomics, to provide researchers with a more holistic view of biological systems. According to experts at the ELRIG Drug Discovery 2025 event, this system-level view is essential for understanding disease mechanisms and supporting more rational drug design.
Platforms that integrate machine learning with omics data and spatial transcriptomics are identifying novel therapeutic strategies across the pharmaceutical industry. Companies like Exscientia and Evotec utilize generative design models and simulation-guided clinical trial planning, marking a shift from empirical to computationally guided therapeutic development.
The convergence of patient-centric real-world evidence tools, electronic health records, multi-omics profiling, digital biomarkers, and AI-based data analysis is paving the way towards biomarker-enabled algorithm-based precision research and development. This evolution represents a paradigm shift from one-size-fits-all approaches to biomarker-guided patient-centric medicine.
Future Outlook and Industry Implications
OmicInsight’s strategic investment positions the company to address what its leadership describes as the most critical challenges in precision medicine. The funding will support expansion of AI-driven diagnostics and premium subcellular-level, multi-omics analysis capabilities at scale, enabling deeper insights for drug discovery, precision medicine, and fundamental research.
The spatial biology market is expected to significantly enhance biomarker discovery, drug development, and personalized medicine over the coming decade. As investment, collaborations, and technology adoption accelerate, companies like OmicInsight that can deliver integrated, AI-powered solutions are well-positioned to capture significant market opportunities.
Industry momentum continues to build around antibody-independent spatial omics technologies and rising demand for high-throughput, discovery-driven platforms that enable multi-site reproducibility. The market is rapidly moving toward end-to-end solutions that unify sample preparation, imaging, and multi-omics readouts, a trend that aligns with OmicInsight’s strategic direction.
For pharmaceutical companies seeking to optimize drug pipelines and enhance translational research capabilities, AI-powered spatial omics platforms represent an increasingly essential tool. The ability to provide unprecedented molecular resolution within biological tissues enables deeper insights that can accelerate drug discovery timelines, improve clinical trial design, and ultimately deliver more effective treatments to patients worldwide.
The investment from LOTTE Holdings and participation from existing investor Adelphi Ventures provides OmicInsight with the financial resources and strategic partnerships necessary to execute its ambitious expansion plans. As the company leverages its proprietary technology and new investor relationships, it is positioned to play a significant role in advancing the next generation of precision medicine applications across the global pharmaceutical industry.
About OmicInsight Corporation: OmicInsight Corporation is a biotechnology company focused on delivering high-sensitivity and high-throughput spatial omics analysis powered by proprietary artificial intelligence technology. Headquartered in Santa Clara, California, the company’s platform is designed to provide unprecedented molecular resolution within biological tissues, enabling deeper insights for drug discovery, precision medicine, and fundamental research.
About LOTTE Holdings Co., Ltd.: LOTTE Holdings, based in Tokyo, Japan, manages a diverse global portfolio across food, retail, biopharmaceuticals, and healthcare. Through its Healthcare & Biopharmaceutical Corporate Venture Capital, LOTTE is committed to supporting transformative technologies that address unmet needs in precision medicine.
Ready to take your career to the next level? Join our Online courses: ACCA, HESI A2, ATI TEAS 7 , HESI EXIT , NCLEX – RN and NCLEX – PN, Financial Literacy!🌟 Dive into a world of opportunities and empower yourself for success. Explore more at Serrari Ed and start your exciting journey today! ✨
Track GDP, Inflation and Central Bank rates for top African markets with Serrari’s comparator tool.
See today’s Treasury bonds and Money market funds movement across financial service providers in Kenya, using Serrari’s comparator tools.
photo source: Google
By: Montel Kamau
Serrari Financial Analyst
6th January, 2026
Article, Financial and News Disclaimer
The Value of a Financial Advisor
While this article offers valuable insights, it is essential to recognize that personal finance can be highly complex and unique to each individual. A financial advisor provides professional expertise and personalized guidance to help you make well-informed decisions tailored to your specific circumstances and goals.
Beyond offering knowledge, a financial advisor serves as a trusted partner to help you stay disciplined, avoid common pitfalls, and remain focused on your long-term objectives. Their perspective and experience can complement your own efforts, enhancing your financial well-being and ensuring a more confident approach to managing your finances.
Disclaimer: This article is for informational purposes only and does not constitute financial advice. Readers are encouraged to consult a licensed financial advisor to obtain guidance specific to their financial situation.
Article and News Disclaimer
The information provided on www.serrarigroup.com is for general informational purposes only. While we strive to keep the information up to date and accurate, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability, or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
www.serrarigroup.com is not responsible for any errors or omissions, or for the results obtained from the use of this information. All information on the website is provided on an as-is basis, with no guarantee of completeness, accuracy, timeliness, or of the results obtained from the use of this information, and without warranty of any kind, express or implied, including but not limited to warranties of performance, merchantability, and fitness for a particular purpose.
In no event will www.serrarigroup.com be liable to you or anyone else for any decision made or action taken in reliance on the information provided on the website or for any consequential, special, or similar damages, even if advised of the possibility of such damages.
The articles, news, and information presented on www.serrarigroup.com reflect the opinions of the respective authors and contributors and do not necessarily represent the views of the website or its management. Any views or opinions expressed are solely those of the individual authors and do not represent the website's views or opinions as a whole.
The content on www.serrarigroup.com may include links to external websites, which are provided for convenience and informational purposes only. We have no control over the nature, content, and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorsement of the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, www.serrarigroup.com takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
Please note that laws, regulations, and information can change rapidly, and we advise you to conduct further research and seek professional advice when necessary.
By using www.serrarigroup.com, you agree to this disclaimer and its terms. If you do not agree with this disclaimer, please do not use the website.
www.serrarigroup.com, reserves the right to update, modify, or remove any part of this disclaimer without prior notice. It is your responsibility to review this disclaimer periodically for changes.
Serrari Group 2025
